CDK4 and breast carcinoma: Palbociclib, in contrast, acts further downstream (Figure 1) and was included in this analysis given its role in the inavolisib regimen as well as prior reports linking CDK4/6 inhibitors to an increased risk of stomatitis in breast cancer patients [28].